Eli Lilly LLY Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $25.28B+128% | $20.64B+94.9% | $18.41B+120% | $13.8B+88.0% | $11.11B+80.9% | ||
| $2.04B+11.7% | $2B+13.0% | $1.9B+13.6% | $1.89B+17.3% | $1.83B+16.9% | ||
| $633M-1.2% | $626M-3.1% | $632.2M+1.2% | $614.3M-13.1% | $640.6M-2.5% | ||
| —— | —— | —— | $2.86B+8.3% | $2.8B+35.7% | ||
| —— | $4.67B+86.3% | $4.13B+84.7% | $3.59B+82.6% | $3.05B+79.8% | ||
| —— | $10.19B+290% | $8.29B+174% | $6.4B+85.9% | $4.5B+16.7% | ||
| —— | $6.61B+98.4% | $5.79B+72.2% | $4.97B+46.5% | $4.15B+21.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | $7B+225% | $5.79B+160% | $4.58B+98.8% | $3.37B+41.6% | ||
| $20.48B+120% | $16.81B+90.7% | $16.06B+153% | $10.94B+127% | $9.32B+134% | ||
| $8.66B+55.1% | $7.84B+55.0% | $6.79B+46.6% | $6.05B+42.4% | $5.58B+48.2% | ||
| $1.72B— | $661M— | $549.7M— | —— | —— | ||
| $745M-1.6% | $645M-4.7% | $669.9M-14.3% | $794.8M+24.6% | $756.9M+7.8% | ||
| $141M+58.8% | -$1M-100% | $734M— | $329.8M— | $88.8M— | ||
| —— | —— | —— | —— | —— | ||
| -$11.54B-0.5% | -$10.97B-18.0% | -$10.09B+2.1% | -$11.11B-18.5% | -$11.48B-50.2% | ||
| $5.59B+15.0% | $5.38B+15.0% | $5.21B+14.9% | $5.03B+15.0% | $4.86B+15.1% | ||
| $5.26B+42.3% | $4.11B+64.3% | $4.65B— | $4.39B— | $3.7B— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $1.11B+234% | $498M+200% | ||
| -$677M+14.0% | -$772M-57.2% | -$792.8M-66.3% | -$809.9M-85.7% | -$787.2M-77.4% | ||
| —— | —— | —— | —— | —— | ||
| -$7.06B— | -$2.21B— | —— | —— | —— | ||
| —— | —— | $10.3M-96.1% | $205.5M+415% | -$129.5M-219% | ||
| —— | —— | —— | —— | —— | ||
| —— | $7B+225% | $5.79B+160% | $4.58B+98.8% | $3.37B+41.6% | ||
| —— | —— | —— | $2.86B+8.3% | $2.8B+35.7% | ||
| —— | $6.61B+98.4% | $5.79B+72.2% | $4.97B+46.5% | $4.15B+21.3% | ||
| $1.92B-59.5% | $2.91B-11.3% | $2.57B-30.8% | $4.74B+22.7% | $4.74B+24.6% | ||
| $1.72B— | $661M— | $549.7M— | —— | —— | ||
| $141M+58.8% | -$1M-100% | $734M— | $329.8M— | $88.8M— | ||
| $1.46B-70.9% | $3.01B-10.1% | $2.84B-22.8% | $4.94B+27.0% | $5.01B+31.6% | ||
| $745M-1.6% | $645M-4.7% | $669.9M-14.3% | $794.8M+24.6% | $756.9M+7.8% | ||
| $8.66B+55.1% | $7.84B+55.0% | $6.79B+46.6% | $6.05B+42.4% | $5.58B+48.2% | ||
| -$677M+14.0% | -$772M-57.2% | -$792.8M-66.3% | -$809.9M-85.7% | -$787.2M-77.4% | ||
| —— | —— | —— | —— | —— | ||
| $11.82B+216% | $8.97B+139% | $9.27B— | $4.88B— | $3.74B— | ||
| $11.82B+216% | $8.97B+139% | $9.27B— | $4.88B— | $3.74B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Eli Lilly generate?
- Eli Lilly (LLY) generated $20.5B in operating cash flow over the trailing twelve months.
- What is Eli Lilly's free cash flow?
- After $8.7B of capital expenditures, Eli Lilly's free cash flow was $11.8B over the trailing twelve months, up 216.4% year over year.
- Where does Eli Lilly's cash flow data come from?
- Every line is extracted from Eli Lilly's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
